ImClone info requested
House Committee asks for records from seven drug companies.
February 21, 2002: 8:04 p.m. ET
|
NEW YORK (CNN/Money) - A U.S. House of Representatives investigative panel has asked seven major drug companies to turn over all records involving strategic partnership discussions with ImClone Systems.
The House Energy and Commerce Committee has asked for all pertinent documents from companies which talked to ImClone (IMCL: down $1.12 to $16.77, Research, Estimates) about a possible partnership for the cancer drug Erbitux, before the biotech made a deal with Bristol-Myers Squibb Co.
The companies listed are Pharmacia Corp. (PHA: Research, Estimates), Merck & Co. Inc. (MRK: Research, Estimates), Eli Lilly & Co. (LLY: Research, Estimates), Johnson & Johnson (JNJ: Research, Estimates), Chiron Corp. (CHIR: Research, Estimates), Amgen Inc. (AMGN: down $1.36 to $57.59, Research, Estimates) and Abbott Laboratories (ABT: Research, Estimates).
In a letter to each of the companies, the Committee requested "all records including internal audits, investigations, and/or reports relating to ImClone Systems" by Feb. 28.
The Committee said while no deal came about, it understands each of the companies conducted due diligence efforts relating to Erbitux and ImClone.
The Committee's investigation was first announced on Jan. 18.
ImClone has been hit with a number of class-action suits from investors alleging that CEO Sam Waksal made misleading statements concerning the approval process for its cancer drug Erbitux. 
|
| SPECIAL: |
|
|
|
|
|
|
